A REVIEW OF PHARMACOLOGICAL ADVANCES IN THE MANAGEMENT OF GERD, 2015-2025
Abstract
Background: Gastroesophageal reflux disease (GERD) remains one of the most prevalent gastrointestinal disorders worldwide. Between 2015 and 2025, advances in understanding its multifactorial pathophysiology have driven significant changes in pharmacological management.
Aim: This review summarizes key developments in GERD pathophysiology and evaluates significant pharmacological advances from 2015 to 2025, including comparative safety profiles, limitations of current therapies, and emerging treatment directions.
Methods: A structured search of PubMed, Google Scholar, and major open-access databases was performed using keywords related to GERD, pathophysiology, proton pump inhibitors, P-CABs, prokinetics, neuromodulators, and novel therapies.
Results: Proton pump inhibitors remain first-line therapy but show variable efficacy in non-erosive disease and refractory symptoms. Newer agents such as potassium-competitive acid blockers, modern prokinetics, alginate-based formulations, neuromodulators, and mucosal protectants offer therapeutic benefits in selected phenotypes. Comparative analyses highlight the importance of optimizing long-term PPI use and monitoring potential adverse effects. Advances in diagnostics and improved understanding of sensory and functional mechanisms have enabled more individualized treatment strategies.
Conclusions: Pharmacological management of GERD has evolved substantially over the past decade, shifting toward mechanism-based and patient-specific therapy. Future progress will depend on integrating high-resolution diagnostics, refining reflux phenotypes, and developing novel treatments that target mucosal integrity, hypersensitivity, and non-acid reflux.
References
V. Savarino, E. Marabotto, P. Zentilin, M. G. Demarzo, N. de Bortoli, and E. Savarino, “Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art,” Drug Design Development and Therapy. Dove Medical Press, p. 1609, Apr. 01, 2021. doi: 10.2147/dddt.s306371.
F. Rettura et al., “Refractory Gastroesophageal Reflux Disease: A Management Update,” Frontiers in Medicine, vol. 8. Frontiers Media, Nov. 01, 2021. doi: 10.3389/fmed.2021.765061.
Z. Al-Frejat, N. Martini, A. M. Esper, D. Al-Frejat, S. Younes, and M. Hanna, “GERD: Latest update on acid-suppressant drugs,” Current Research in Pharmacology and Drug Discovery, vol. 7, p. 100198, Jan. 2024, doi: 10.1016/j.crphar.2024.100198.
K. Ramnani, S. Mukherjee, and D. Bisharah, “Review of emerging therapy in refractory GERD- an evidence based approach,” Gastroenterology & Hepatology Open Access, vol. 9, no. 4, Aug. 2018, doi: 10.15406/ghoa.2018.09.00315.
K. Fuchs and A. Meining, “Current Insights in the Pathophysiology of Gastroesophageal Reflux Disease,” Chirurgia, vol. 116, no. 5. p. 515, Jan. 01, 2021. doi: 10.21614/chirurgia.116.5.515.
J. Argüero and D. Sifrim, “Pathophysiology of gastro-oesophageal reflux disease: implications for diagnosis and management,” Nature Reviews Gastroenterology & Hepatology, vol. 21, no. 4. Nature Portfolio, p. 282, Jan. 04, 2024. doi: 10.1038/s41575-023-00883-z.
A. Wilks, L. Panahi, G. Udeani, and S. Surani, “Review of Gastroesophageal Reflux Pharmacotherapy Management,” in IntechOpen eBooks, IntechOpen, 2022. doi: 10.5772/intechopen.106338.
H. Shang, H. Mao, J. Wang, X. Tian, K. Zheng, and J. Wang, “Optimizing acid-related disease management: insights into potassium-competitive acid blockers and proton pump inhibitors,” European Journal of Clinical Pharmacology. Springer Science+Business Media, Oct. 07, 2025. doi: 10.1007/s00228-025-03912-9.
E. Marabotto et al., “The Clinical Spectrum of Gastroesophageal Reflux Disease: Facts and Fictions,” Visceral Medicine, vol. 40, no. 5. Karger Publishers, p. 242, Mar. 13, 2024. doi: 10.1159/000536583.
P. Sharma and R. Yadlapati, “Pathophysiology and treatment options for gastroesophageal reflux disease: looking beyond acid,” Annals of the New York Academy of Sciences, vol. 1486, no. 1. Wiley, p. 3, Oct. 04, 2020. doi: 10.1111/nyas.14501.
S. Shimoyama, “Challenges to Unravel Mechanisms of GERD,” in IntechOpen eBooks, IntechOpen, 2019. doi: 10.5772/intechopen.80793.
F. Tanvir et al., “Gastroesophageal Reflux Disease: New Insights and Treatment Approaches,” Cureus. Cureus, Inc., Aug. 24, 2024. doi: 10.7759/cureus.67654.
E. Savarino, A. J. Bredenoord, M. Fox, J. E. Pandolfino, S. Roman, and C. P. Gyawali, “Advances in the physiological assessment and diagnosis of GERD,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 11. Nature Portfolio, p. 665, Sep. 27, 2017. doi: 10.1038/nrgastro.2017.130.
J. P. Kothadia and C. W. Howden, “Potassium-Competitive Acid Blockers for the Treatment of Gastroesophageal Reflux Disease,” Foregut The Journal of the American Foregut Society, vol. 4, no. 1, p. 7, Jul. 2023, doi: 10.1177/26345161231181357.
N. de Bortoli, “Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders,” Annals of Gastroenterology. Hellenic Society of Gastroenterology, Jan. 01, 2018. doi: 10.20524/aog.2018.0314.
G. Domingues, D. Chinzon, J. P. Moraes-Filho, J. Senra, M. Perrotti, and S. Zaterka, “Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review,” Gastroenterology Review, vol. 18, no. 1. Termedia Publishing House, p. 47, Aug. 18, 2022. doi: 10.5114/pg.2022.116673.
T. Oshima and H. Miwa, “Potent Potassium-competitive Acid Blockers: A New Era for the Treatment of Acid-related Diseases,” Journal of Neurogastroenterology and Motility, vol. 24, no. 3. The Korean Society of Neurogastroenterology and Motility, p. 334, May 09, 2018. doi: 10.5056/jnm18029.
C. Scarpignato and R. H. Hunt, “Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments,” Current Gastroenterology Reports, vol. 26, no. 11. Springer Science+Business Media, p. 273, Aug. 15, 2024. doi: 10.1007/s11894-024-00939-3.
P. Singh, N. Singh, and G. Palit, “Current Scenario of Pharmacological Approaches for Gastroesophageal Reflux Disease,” Pharmacologia, vol. 3, no. 8, p. 275, Nov. 2011, doi: 10.5567/pharmacologia.2012.275.282.
C. Tsai, Y. Li, L.-C. Chang, S. Tey, K.-J. Lin, and S. Huang, “Long-Chain Fatty Acid Receptors Mediate Relaxation of the Porcine Lower Esophageal Sphincter,” Frontiers in Physiology, vol. 10, May 2019, doi: 10.3389/fphys.2019.00676.
P. J. Kahrilas, G. E. Boeckxstaens, and A. J. P. M. Smout, “Management of the patient with incomplete response to PPI therapy,” Best Practice & Research Clinical Gastroenterology, vol. 27, no. 3. Elsevier BV, p. 401, Jun. 01, 2013. doi: 10.1016/j.bpg.2013.06.005..
A. Young, M. A. Kumar, and P. N. Thota, “GERD: A practical approach,” Cleveland Clinic Journal of Medicine, vol. 87, no. 4. Cleveland Clinic, p. 223, Apr. 01, 2020. doi: 10.3949/ccjm.87a.19114.
K. Iwakiri et al., “Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015,” Journal of Gastroenterology, vol. 51, no. 8. Springer Science+Business Media, p. 751, Jun. 21, 2016. doi: 10.1007/s00535-016-1227-8.
K. Hossa and E. Małecka‐Panas, “Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies,” Pharmaceuticals, vol. 18, no. 5. Multidisciplinary Digital Publishing Institute, p. 699, May 09, 2025. doi: 10.3390/ph18050699.
K. Z. Huang and H. C. Weber, “Potassium-competitive acid blockers and acid-related disorders,” Current Opinion in Endocrinology Diabetes and Obesity, vol. 31, no. 3. Lippincott Williams & Wilkins, p. 107, Mar. 14, 2024. doi: 10.1097/med.0000000000000858.
N. Zhang et al., “A scientometrics analysis and visualization of refractory gastroesophageal reflux disease,” Frontiers in Pharmacology, vol. 15, Jul. 2024, doi: 10.3389/fphar.2024.1393526.
E. S. Dellon and N. J. Shaheen, “Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease,” Carolina Digital Repository (University of North Carolina at Chapel Hill), Jan. 2010, doi: 10.17615/r8x3-s912.
R. Yadlapati and K. DeLay, “Proton Pump Inhibitor–Refractory Gastroesophageal Reflux Disease,” Medical Clinics of North America, vol. 103, no. 1. Elsevier BV, p. 15, Nov. 01, 2018. doi: 10.1016/j.mcna.2018.08.002.
S. H. Kim et al., “Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease,” Alimentary Pharmacology & Therapeutics, vol. 54, no. 4, p. 402, Jul. 2021, doi: 10.1111/apt.16477.
S. Ahmed et al., “Comparing Proton Pump Inhibitors and Emerging Acid-Suppressive Therapies in Gastroesophageal Reflux Disease: A Systematic Review,” Cureus. Cureus, Inc., May 17, 2025. doi: 10.7759/cureus.84311.
C. Xue et al., “Evaluating Vonoprazan and Tegoprazan for Gastroesophageal Reflux Disease Treatment in Chinese Healthcare: An EVIDEM Framework Analysis,” Research Square (Research Square), Feb. 2024, doi: 10.21203/rs.3.rs-3930251/v1.
D. M. Simadibrata, A. F. Syam, and Y. Y. Lee, “A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis,” Journal of Gastroenterology and Hepatology, vol. 37, no. 12. Wiley, p. 2217, Oct. 01, 2022. doi: 10.1111/jgh.16017.
S. H. Kang et al., “Efficacy and safety of on-demand tegoprazan therapy in gastroesophageal reflux disease: A multicentre, double-blind, randomised, active-controlled pilot study,” Research Square (Research Square), Nov. 2024, doi: 10.21203/rs.3.rs-5062207/v1.
V. Padwale, V. Kirnake, R. Daswani, A. Kodmalwar, and A. Gupta, “A Comprehensive Review on the Efficacy and Safety of Vonoprazan in the Management of Gastric Acid-Related Diseases,” Cureus, vol. 16, no. 7. Cureus, Inc., Jul. 17, 2024. doi: 10.7759/cureus.64777.
V. Lanari et al., “Efficacy and Safety of Vonoprazan as Treatment and Long-term Management of Peptic Ulcer: A Systematic Review and Meta-Analysis,” Research Square (Research Square). Research Square (United States), Nov. 08, 2024. doi: 10.21203/rs.3.rs-5397106/v1.
Y. Dong, H. Xu, Z. Zhang, Z. Zhou, and Q. Zhang, “Comparative efficiency and safety of potassium competitive acid blockers versus Lansoprazole in peptic ulcer: a systematic review and meta-analysis,” Frontiers in Pharmacology, vol. 14. Frontiers Media, Jan. 11, 2024. doi: 10.3389/fphar.2023.1304552.
C. W. Howden, “The role of P-CABs in GERD,” The American Journal of Gastroenterology. Lippincott Williams & Wilkins, Oct. 17, 2024. doi: 10.14309/ajg.0000000000003140.
S. Vinayagam, N. Mittal, and J. Kaushal, “Vonoprazan: a promising advancement in proton pump inhibitor therapy,” International Journal of Basic & Clinical Pharmacology, vol. 13, no. 4, p. 573, Jun. 2024, doi: 10.18203/2319-2003.ijbcp20241662.
B. Zhu et al., “Current research status and trends of potassium-competitive acid blockers in the treatment of acid-related diseases: a bibliometric analysis,” Frontiers in Pharmacology, vol. 15, p. 1477633, Jan. 2025, doi: 10.3389/fphar.2024.1477633.
R. H. Hunt, C. Scarpignato, R. H. Hunt, and C. Scarpignato, “Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?,” Clinical and Translational Gastroenterology, vol. 6, no. 10, Oct. 2015, doi: 10.1038/ctg.2015.39.
G. N. J. Tytgat, “Gastro Update Europe 2020,” Digestive Diseases, vol. 40, no. 2. Karger Publishers, p. 246, Mar. 24, 2021. doi: 10.1159/000516085.
R. H. Hunt and C. Scarpignato, “Potent Acid Suppression with PPIs and P-CABs: What’s New?,” Current Treatment Options in Gastroenterology, vol. 16, no. 4. Springer Science+Business Media, p. 570, Oct. 25, 2018. doi: 10.1007/s11938-018-0206-y.
R. Cioeta et al., “Effectiveness and tolerability of Poliprotect, a natural mucosal protective agent for gastroesophageal reflux disease and dyspepsia: Surveys from patients, physicians, and pharmacists,” Frontiers in Drug Safety and Regulation, vol. 2, Oct. 2022, doi: 10.3389/fdsfr.2022.969831.
R. Yadlapati et al., “Management Options for Patients With GERD and Persistent Symptoms on Proton Pump Inhibitors: Recommendations From an Expert Panel,” The American Journal of Gastroenterology, vol. 113, no. 7, p. 980, Apr. 2018, doi: 10.1038/s41395-018-0045-4.
N. C. Wickramasinghe and N. M. Devanarayana, “Unveiling the intricacies: Insight into gastroesophageal reflux disease,” World Journal of Gastroenterology, vol. 31, no. 1. Baishideng Publishing Group, p. 98479, Dec. 09, 2024. doi: 10.3748/wjg.v31.i1.98479.
P. J. Kahrilas et al., “The tapestry of reflux syndromes: translating new insight into clinical practice,” British Journal of General Practice, vol. 71, no. 711, p. 470, Sep. 2021, doi: 10.3399/bjgp21x717329.
J. I. Bucan, T. Braut, A. Kršek, V. S. Tokmadžić, and L. Batičić, “Updates in Gastroesophageal Reflux Disease Management: From Proton Pump Inhibitors to Dietary and Lifestyle Modifications,” Gastrointestinal Disorders, vol. 7, no. 2, p. 33, Apr. 2025, doi: 10.3390/gidisord7020033.
T. Zhang et al., “Trends in gastroesophageal reflux disease research: A bibliometric and visualized study,” Frontiers in Medicine, vol. 9, Sep. 2022, doi: 10.3389/fmed.2022.994534.
Copyright (c) 2026 Aleksandra Markuszewska, Agnieszka Anna Bugała, Julia Wendt, Adam Andrzejewski, Dominika Raether, Olga Wcisłek, Urszula Chmielecka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
